A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Abroad (travel likely)RecruitingPHASE2
Conditions
Non-Small Cell Lung Cancer With EGFR Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hanhui Cancer Hospital, Hefei, Anhui, China
Contact: Study coordinator (Yueyin Pan)Contact: Principal Investigator (Yueyin Pan)Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Contact: Study coordinator (Yan Yu)Contact: Principal Investigator (Yan Yu)Union Hospital Tongji Medical College Huzhong University of Science and Techology, Wuhan, Hubei, China
Contact: Study coordinator (Xiaorong Dong)Contact: Principal Investigator (Xiaorong Dong)Jilin Cancer Hospital, Changchun, Jilin, China
Contact: Study coordinator (Ying Cheng)Contact: Principal Investigator (Ying Cheng)Shanghai Chest Hospital, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Shun Lu)Contact: Principal Investigator (Shun Lu)